Public company intelligence preview
AIRSCULPT TECHNOLOGIES INC
35 insider trades surfaced from the last year. This page shows only aggregate signals, not the underlying transactions, people, filings, filters, or AI workspace.
Snapshot
A narrow read on a much deeper workspace.
The preview gives search visitors enough signal to understand coverage. It does not expose transaction records, person-level profiles, filters, comparisons, or analyst workflows.
Insider compensation
Public aggregate: $5.5M average total compensation across covered insiders.
Governance movement
Public aggregate: 5 governance events in the last year.
Institutional ownership
Public aggregate: 92 holders from the latest quarter.
Restricted sales and governance
Public counts, not the investigation layer.
The full product opens the underlying filings, insider context, historical holdings, comparison tools, and AI analysis.
Market context
Basic quote context for the preview.
Company note
Context before the data.
Company Overview
AirSculpt Technologies Inc. is a Healthcare company in the Medical Care Facilities industry that operates a premium aesthetic medicine platform focused on minimally invasive body contouring procedures. Its core offering is the patented AirSculpt method, and the business is built around exclusive centers, surgeon-owned clinical entities, and company-owned administrative infrastructure. Recent filing summaries show the company faced a difficult 2025, with revenue down to $151.8 million and case volume declining materially as broader aesthetics demand softened. The company is also managing liquidity carefully, with paused de novo openings, a London facility closure, and a focus on new product development and consumer financing to restore growth.
Executive Compensation Practices
Executive compensation at a company like AirSculpt is likely to be tied closely to case volume growth, revenue per case, center utilization, EBITDA, and cash flow, since these are the core operational drivers in its business model. Because revenue is collected upfront and there is no reimbursement risk, management incentives may also emphasize conversion rates, marketing efficiency, and successful expansion of financing options that support demand. Given the 2025 decline in revenue and the company’s cost-reduction actions, compensation outcomes may be under pressure if bonuses are linked to adjusted EBITDA, same-center growth, or liquidity milestones. In the Healthcare sector, especially within the Medical Care Facilities industry, equity awards and retention-focused compensation are common, but performance targets may also reflect compliance, clinic expansion, and patient volume metrics rather than only broad financial results.
Insider Trading Considerations
Insider trading activity in AirSculpt may be especially sensitive to short-term operating trends because the business is highly exposed to discretionary consumer demand in the aesthetics market. Executives and directors may trade around visibility into same-center case trends, marketing effectiveness, financing adoption, and any signs of stabilization in demand, since these can materially affect near-term results. The company’s liquidity profile, debt maturities in 2027, covenant compliance, and restructuring or refinancing efforts could also be important catalysts for insider transactions. Because AirSculpt operates in a regulated healthcare structure with corporate practice of medicine and fee-splitting considerations, insiders may face additional trading caution around legal or regulatory developments that could affect the company’s operating model or center economics.
Unlock the full AIRS insider intelligence workspace.
Move from public aggregate counts into transaction-level detail, people, filings, compensation history, ownership shifts, export tools, and AI-assisted analysis.